Need a quick boost of motivation but don’t feel like reading a whole blog? Then check out our mini blogs! The messages are condensed into miniature cards so that each are readable in less than five minutes!
Mini Blogs
3 Comments
Leave a Reply
You must be logged in to post a comment.
Kyndall; What a great idea. I like the short stories and your very positive attitude.
Thank you! Trust me, it’s taken a while to build up this perspective. There are many things I’m still working on too that might be my topic for this time next year!
fevipiprant (inn; code name qaw039) is a drug being developed by novartis which acts as a selective, orally available antagonist of the prostaglandin d2 receptor 2 (dp2 or crth2).
as of 2016, it is in phase iii clinical trials for the treatment of asthma.
on monday, december 16, 2019, switzerland-based novartis officially announced that it was jettisoning fevipiprant from its development program, given that the medicine has failed in two additional clinical trials in patients with moderate-to-severe asthma. the firm said that it had hoped fevipiprant would be a billion-dollar-selling asthma drug.